FTC departure
This article was originally published in The Tan Sheet
Executive Summary
Deputy Director of the Bureau of Competition Ann Malester is leaving the Federal Trade Commission to enter private practice, FTC announces Jan. 21. From 1991 to 2003, Malester served as the Bureau's Assistant Director of Mergers I, one of four merger divisions, reviewing proposed mergers and obtaining consumer relief. She has worked on several pharmaceutical and biotech mergers, including Pfizer/Pharmacia and Glaxo/SmithKlineBeecham, as well as on several FTC court cases such as American Medical Association vs. FTC...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.